세계 암 진단 시장 규모는 2023년 1,251억 3,000만 달러, 2030년까지 2,148억 8,000만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 연평균 9.43% 성장할 전망입니다. 암 진단 제품 및 서비스에 대한 수요 증가는 전 세계적으로 보고된 암 환자의 급증에 기인합니다. 또한, 첨단 암 진단 제품 개발에 주력하는 제조업체 증가, 다양한 암 진단 실험실의 설립, 환자의 암 조기 발견 및 관리에 대한 인식을 높이기 위한 정부의 이니셔티브 증가 등이 향후 몇 년동안 세계 암 진단 시장을 견인할 것으로 예상됩니다.
암 진단 시장 역학
암 진단 시장은 전 세계 암 환자의 급증으로 인해 현재 추진력을 얻고 있으며, GLOBOCAN이 2020년 발표한 데이터에 따르면 전 세계적으로 약 1,929만 2,789건의 새로운 암 사례가 보고되었습니다. 또한, 세계보건기구(WHO)의 2022년 자료에 따르면, 2020년 전 세계적으로 약 1,000만 명이 암으로 사망할 것으로 추정됩니다. 따라서 적절한 암 관리를 위해서는 암의 조기 발견이 필요하며, 이는 암 진단에 대한 수요 증가로 이어져 시장을 주도하고 있습니다.
또한 위의 데이터에 따르면 담배 사용, 알코올 사용, 건강에 해로운 식습관, 운동 부족, 발암성 감염 및 대기 오염은 암의 위험 요소입니다. 예를 들어, WHO(2022)에 따르면 2018 년에 진단 된 암의 약 13%는 헬리코박터 파일로리, 인유두종 바이러스(HPV), B 형 간염 바이러스, C 형 간염 바이러스, 엡스타인 바 바이러스와 같은 발암성 감염에 기인합니다.
또한, 다양한 암 진단 제품 개발의 기술 혁신도 향후 몇 년동안 시장에 기여할 수 있습니다. 암 진단의 정확성, 속도, 효율성을 향상시키는 AI 기술을 암 치료에 통합하는 것도 암 진단 시장을 촉진할 것으로 예상됩니다. 예를 들어, 2022년 11월 FDA는 유방암을 검출하는 Lunit AI 솔루션에 510(k) 승인을 부여했습니다.
따라서 앞서 언급한 모든 요인들이 예측 기간 동안 암 진단 시장을 강화할 것으로 예상됩니다.
그러나 암 영상 진단 장비에 따른 부작용과 암 진단 제품의 높은 비용은 세계 암 진단 시장을 저해할 가능성이 높습니다.
또한, 전례 없는 코로나19 팬데믹은 암 진단 시장에 부정적인 영향을 미쳤습니다. 전 세계 대부분의 국가가 감염 확산을 막기 위해 엄격한 규제를 시행했기 때문입니다. 또한, 의료 시스템의 역량을 유지하고 고위험군 환자를 바이러스에 노출되지 않도록 보호하는 데 중점을 두면서 암 환자들은 치료 접근성에 대한 도전이 증가했습니다. 예를 들어, 국립암연구소(National Cancer Institute, 2022)가 제공한 데이터에 따르면, 코로나19 팬데믹으로 인한 봉쇄 제한과 관련된 문제 외에도 2020년 3월에만 코로나19로 인해 800건 이상의 폐암 검진 예약이 연기된 것으로 확인되었습니다. 연기된 것으로 확인되었습니다.
암 진단 시장 부문별 분석
암 진단 제품 유형 제품 유형 부문에서는 시약 및 키트 유형이 66%로 가장 큰 시장 점유율을 차지하고 있으며, 이러한 추세는 예측 기간 동안에도 지속될 것으로 보입니다. 이는 암세포의 세포 신호 전달, 세포 증식 및 생존율, 암 억제 유전자, 생리활성 단백질 등을 검출하는 데 사용되는 시약 및 키트가 광범위하게 사용되기 때문입니다.
또한, 다양한 유형의 암을 조기에 발견하고 적절하게 관리할 수 있는 새로운 시약 및 키트가 규제 당국의 승인을 받은 것도 이 부문 시장 성장을 가속할 것으로 예상됩니다.
예를 들어, 혁신적인 차세대 염기서열 분석(NGS) 솔루션 체외진단(IVD) 기업 Pillar Biosciences는 2022년 8월 5일 비소세포폐암(NSCLC) 및 대장암(CRC) 종양 유래 DNA의 체세포 돌연변이를 정량적으로 검출하는 NGS 조직 기반 동반진단 검사인 oncoReveal(TM) Dx Lung and Colon Cancer Assay의 시판 전 승인(PMA)을 획득했습니다.
이 보고서는 세계 암 진단 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.
Cancer Diagnostic Market By Type (Product Type [Reagent & Kits And Instruments], And Services), By Technique (Molecular Diagnostic [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry], Diagnostic Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans], Endoscopy, Biopsy [Standard Biopsy And Liquid Biopsy]), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Others), by geography, is expected to grow at a significant CAGR forecast till 2030 owing to the growing burden cancer across the globe and rise in various product launches for efficient detection of cancer
The global cancer diagnostic market was valued at USD 125.13 billion in 2023, growing at a CAGR of 9.43% during the forecast period from 2024 to 2030, to reach USD 214.88 billion by 2030. The increase in demand for cancer diagnostic products and services is predominantly attributed to the spike in the cancer cases reported worldwide. In addition, growing manufacturers focus to develop advanced cancer diagnostic products, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among the patients, and others are anticipated to drive the global cancer diagnostic market during the forthcoming years.
Cancer Diagnostic Market Dynamics:
The market for cancer diagnostics is gaining momentum at present due to the surge in cancer cases across the globe. According to the data published by the GLOBOCAN in the year 2020, approximately 19,292,789 new cases of cancer were reported worldwide. Furthermore, as per the World Health Organization (WHO) 2022 data, cancer accounted for an estimated 10 million deaths across the globe in the year 2020. Thus, for proper cancer management, early detection of cancer is necessary which would lead to an increased demand for cancer diagnosis thereby propelling the market.
Additionally, as per the above-mentioned data, tobacco use, alcohol use, unhealthy diet, physical inactivity, carcinogenic infections, and air pollution are some of the risk factors for cancer. For instance, in the year 2018, about 13% of cancer diagnosed were attributed to carcinogenic infections such as Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus, as per the WHO, 2022.
Furthermore, technical innovation in the development of a variety of cancer diagnostic products would also contribute to the market in the forthcoming years. Integration of Artificial Intelligence (AI) technology in cancer care to improve the accuracy, speed and efficiency of cancer detection will also boost the cancer diagnostic market. For instance, in November 2022, FDA granted 510(k) clearance for Lunit AI solution to detect breast cancer.
Hence, all the aforementioned factors are projected to bolster the cancer diagnostic market during the forecasted period.
However, side effects associated with cancer imaging devices and the high cost of cancer diagnostic products are likely to impede the global cancer diagnostic market.
Additionally, the unprecedented COVID-19 pandemic had a negative impact on the cancer diagnostic market. This is due to the implementation of stringent regulations by most nations worldwide to curb infection transfer. Moreover, owing to the shift in focus on preserving health system capacity and also protecting high-risk patients from exposure to the virus, cancer patients have faced increased challenges in accessing care. For instance, as per the data provided by the National Cancer Institute 2022, besides the challenges associated with the lockdown restrictions due to the COVID-19 pandemic, it was observed that in March 2020 alone, COVID-19 forced the postponement of more than 800 appointments for lung cancer screening.
Cancer Diagnostic Market Segment Analysis:
Cancer Diagnostic Market By Type (Product Type [Reagent & Kits And Instruments], And Services), By Technique (Molecular Diagnostic [Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry], Diagnostic Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans], Endoscopy, Biopsy [Standard Biopsy and Liquid Biopsy]), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Cancer Diagnostic product type segment, the reagents & kits type held a significant market share of 66% which is expected to continue during the forecasted period. This is owing to the wide availability of reagents & kits for detecting cell signalling, cell proliferation and viability, tumor suppressor gene, bioactive proteins, and others in cancer cells.
Furthermore, approval of novel reagents and kits, which aid in early detection and proper management of various cancer types, by the regulatory bodies is also expected to boost the market growth for this segment.
For instance, on August 05, 2022, Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, received the Premarket Approval (PMA) for its oncoReveal(TM) Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.
Also, rising research and development activities by the key manufacturers are another factor projected to contribute to the segmental growth of the cancer diagnostic market. For instance, in the year 2020, BD started a clinical trial to verify the clinical effectiveness of the HPV Nucleic Acid Genotyping Assay Kit for cervical cancer.
Thus, all the above-mentioned factors are expected to propel the cancer diagnostic market in the upcoming years.
North America is expected to dominate the overall Cancer Diagnostic Market:
Among all the regions, North America has occupied a major share of 42% in the overall Cancer Diagnostic market in 2020 and will continue to dominate during the forecasted period. This domination is due to significant factors such as the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management, among others.
For instance, as per the GLOBOCAN 2020 data, approximately, 2,281,658 people were diagnosed with cancer in the US in 2020.
Furthermore, the rise in smoking among adults in the country could be a potential factor for lung cancer development which would, in turn, increase the cancer diagnostic market.
For instance, as per the CDC 2020 data, an estimated 34.1 million adults in the United States smoked cigarettes in 2019.
Moreover, approval of products to enhance the imaging technology for various cancer detection would also contribute to the market. Recently, on November 29, 2022, FDA approved Cytalux (pafolacianine), a targeted fluorescent imaging agent intended to assist surgeons in identifying ovarian cancer lesions.
Hence, the interplay of all the above-mentioned factors will augment the cancer diagnostic market in the country during the forecasted period.
Further, the Asia Pacific region has the future potential for the Cancer Diagnostic market. This is predominantly due to the burgeoning cases of cancer, rising risk factors among the population that potentially lead to the development of cancer, growing government initiatives regarding cancer care and its detection, among others. For instance, New Zealand launched Cancer Action Plan 2019-2029, the plans enable the Cancer Control Agency, the Ministry of Health, the sector, and all those affected by cancer to work collaboratively to prevent cancer and improve detection, diagnosis, treatment, and care after treatment. Thus, all the factors stated above will make APAC the fastest growing cancer diagnostic market in the forthcoming years.
Cancer Diagnostic Market Key Players:
Some of the key market players operating in the Cancer Diagnostic market include Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, and others.
Recent Developmental Activities in the Cancer Diagnostic Market:
In November 2022, Hologic, Inc. commercially launched its new Genius(TM) Digital Diagnostics System in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women.
In June 2022, NeoGenomics completed its acquisition for Inivata Ltd, a global, commercial-stage liquid biopsy platform company headquartered in Cambridge, England.
In August 2020, HTG Molecular Diagnostics, Inc. signed a commercialization and distribution agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly-owned subsidiary of QIAGEN N.V. for companion diagnostic (CDx) assays based on HTG EdgeSeq, HTG's novel RNA platform.
Key Takeaways from the Cancer Diagnostic Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Cancer Diagnostic market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the Global Cancer Diagnostic Market.
Various opportunities available for the other competitor in the Cancer Diagnostic Market space.
What are the top-performing segments in 2023? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Cancer Diagnostic market growth in the coming future?
Target Audience who can be benefited from the Cancer Diagnostic Market Report Study
Cancer Diagnostic providers
Research organizations and consulting companies
Cancer Diagnostic-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in Cancer Diagnostic
Various End-users who want to know more about the Cancer Diagnostic Market and the latest technological developments in the Cancer Diagnostic market.
Frequently Asked Questions for the Cancer Diagnostic Market:
Cancer Diagnostic is a necessary step towards the proper management of cancer and its progression. There is no single test that can accurately diagnose cancer; the complete evaluation usually requires a thorough history and physical examination along with diagnostics testing. Effective diagnostic testing is used to confirm or eliminate the presence of disease, monitor the disease process, and plan for and evaluate the effectiveness of treatment. Diagnostic procedures for cancer may include lab tests, tumor biopsy, endoscopic examination, and imaging.
The global cancer diagnostic market was valued at USD 125.13 billion in 2023, growing at a CAGR of 9.43% during the forecast period from 2024 to 2030, to reach USD 214.88 billion by 2030.
The major factors driving the demand for Cancer Diagnostic are the rising cases of cancer across the globe. Moreover, technological innovation in cancer diagnostic products, increase in product launches, and rise in business expansion activities among key players, and others are expected to propel the cancer diagnostic market.
Some of the key market players operating in the Cancer Diagnostic market include Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, and others.
Among all the regions, North America has occupied a major share of 42% in the overall Cancer Diagnostic market in 2020 and will continue to dominate during the forecasted period. This domination is due to significant factors such as the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management, among others.